nach oben

Tumor Biology

Erschienen in:

05.01.2016 | Original Article

A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice

verfasst von: Jing Wu, Shuye Liu, Zhijuan Fan, Lei Zhang, Yaqiong Tian, Rui Yang

Erschienen in: Tumor Biology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Cell motility and chemotaxis play pivotal roles in the process of tumor development and metastasis. Protein kinase C ζ (PKC ζ) mediates epidermal growth factor (EGF)-stimulated chemotactic signaling pathway through regulating cytoskeleton rearrangement and cell adhesion. The purpose of this study was to develop anti-PKC ζ therapeutics for breast cancer metastasis. In this study, a novel and high-efficient PKC ζ inhibitor named PKC_ZI195.17 was screened out through a substrate-specific strategy. MTT assay was used to determine the cell viability of human breast cancer MDA-MB-231, MDA-MB-435, and MCF-7 cells while under PKC_ZI195.17 treatment. Wound-healing, chemotaxis, and Matrigel invasion assays were performed to detect the effects of PKC_ZI195.17 on breast cancer cells migration and invasion. Adhesion, actin polymerization, and Western blotting were performed to detect the effects of PKC_ZI195.17 on cells adhesion and actin polymerization, and explore the downsteam signaling mechanisms involved in PKC ζ inhibition. MDA-MB-231 xenograft was used to measure the in vivo anti-metastasis efficacy of PKC_ZI195.17. The compound PKC_ZI195.17 selectively inhibited PKC ζ kinase activity since it failed to inhibit PKC α, PKC β, PKC δ, PKC η, AKT2, as well as FGFR2 activity. PKC_ZI195.17 significantly impaired spontaneous migration, chemotaxis, and invasion of human breast cancer MDA-MB-231, MDA-MB-435, and MCF-7 cells, while PKC_ZI195.17 did not obviously inhibited cells viability. PKC_ZI195.17 also inhibited cells adhesion and actin polymerization through attenuating the phosphorylations of integrin β1, LIMK, and cofilin, which might be the downstream effectors of PKC ζ-mediated chemotaxis in MDA-MB-231 cells. Furthermore, PKC_ZI195.17 suppressed the breast cancer metastasis and increased the survival time of breast tumor-bearing mice. In summary, PKC_ZI195.17 was a PKC ζ-specific inhibitor which dampened cancer cell migration and metastasis and may serve as a novel therapeutic drug for breast cancer metastasis.

Thakur S, Singla AK, Chen J, Tran U, Yang Y, Salazar C, et al. Reduced ING1 levels in breast cancer promotes metastasis. Oncotarget. 2014;5(12):4244–56.CrossRefPubMedPubMedCentral

Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14:48. doi:10.1186/s12943-015-0321-5.CrossRefPubMedPubMedCentral

DeCastro AJ, Cherukuri P, Balboni A, DiRenzo J. ΔNP63α transcriptionally activates chemokine receptor 4 (CXCR4) expression to regulate breast cancer stem cell activity and chemotaxis. Mol Cancer Ther. 2015;14(1):225–35. doi:10.1158/1535-7163.MCT-14-0194.CrossRefPubMed

Dillenburg-Pilla P, Patel V, Mikelis CM, Zárate-Bladés CR, Doçi CL, Amornphimoltham P, et al. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/ mTORC1 axis. FASEB J. 2015;29(3):1056–68. doi:10.1096/fj.14-260083.CrossRefPubMed

Feng S, Zhu W. Bidirectional molecular transport shapes cell polarization in a two-dimensional model of eukaryotic chemotaxis. J Theor Biol. 2014;363:235–46. doi:10.1016/j.jtbi.2014.08.033.CrossRefPubMed

Xie L, Lu C, Wu XL. Marine bacterial chemoresponse to a stepwise chemoattractant stimulus. Biophys J. 2015;108(3):766–74. doi:10.1016/j.bpj.2014.11.3479.CrossRefPubMedPubMedCentral

Riahi R, Yang YL, Kim H, Jiang L, Wong PK, Zohar Y. A microfluidic model for organ-specific extravasation of circulating tumor cells. Biomicrofluidics. 2014;8(2):024103. doi:10.1063/1.4868301.eCollection2014.CrossRefPubMedPubMedCentral

Wang F, Lin SL. Knockdown of kinesin KIF11 abrogates directed migration in response to epidermal growth factor-mediated chemotaxis. Biochem Biophys Res Commun. 2014;452(3):642–8. doi:10.1016/j.bbrc.2014.08.136.CrossRefPubMed

Uddin M, Lau LC, Seumois G, Vijayanand P, Staples KJ, Bagmane D, et al. EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma. PLoS One. 2013;8(9):e72502. doi:10.1371/journal.pone.0072502.eCollection2013.CrossRefPubMedPubMedCentral

10.

Ota I, Higashiyama S, Masui T, Yane K, Hosoi H, Matsuura N. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells. Oncol Rep. 2013;30(4):1593–600. doi:10.3892/or.2013.2659.PubMedPubMedCentral

11.

Seshacharyulu P, Ponnusamy MP, Rachagani S, Lakshmanan I, Haridas D, Yan Y, et al. Targeting EGF-receptor(s)-STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget. 2015;6(7):5164–81.CrossRefPubMed

12.

Mori N, Ishikawa C, Senba M. Activation of PKC-δ in HTLV-1-infected T cells. Int J Oncol. 2015;46(4):1609–18. doi:10.3892/ijo.2015.2848.PubMed

13.

Lorimer IA. Atypical PKCι as target for glioblastoma therapy. Curr Cancer Drug Targets. 2015;15(2):136–44.CrossRefPubMed

14.

Martin-Liberal J, Cameron AJ, Claus J, Judson IR, Parker PJ, Linch M. Targeting protein kinase C in sarcoma. Biochim Biophys Acta. 2014;1846(2):547–59. doi:10.1016/j.bbcan.2014.10.002.PubMed

15.

Vorhagen S, Niessen CM. Mammalian aPKC/Par polarity complex mediated regulation of epithelial division orientation and cell fate. Exp Cell Res. 2014;328(2):296–302. doi:10.1016/j.yexcr.2014.08.008.CrossRefPubMed

16.

Chen J, Zhang M. The Par3/Par6/aPKC complex and epithelial cell polarity. Exp Cell Res. 2013;319(10):1357–64. doi:10.1016/j.yexcr.2013.03.021.CrossRefPubMed

17.

Parker PJ, Justilien V, Riou P, Linch M, Fields AP. Atypical protein kinase Cι as a human oncogene and therapeutic target. Biochem Pharmacol. 2014;88(1):1–11. doi:10.1016/j.bcp.2013.10.023.CrossRefPubMed

18.

Iitaka D, Moodley S, Shimizu H, Bai XH, Liu M. PKCδ-iPLA2-PGE2- PPARγ signaling cascade mediates TNF-α induced Claudin 1 expression in human lung carcinoma cells. Cell Signal. 2015;27(3):568–77. doi:10.1016/j.cellsig.2014.12.015.CrossRefPubMed

19.

Zhao X, Rotenberg SA. Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cells. J Biol Chem. 2014;289(37):25844–54. doi:10.1074/jbc.M114.577783.CrossRefPubMedPubMedCentral

20.

Liu ZC, Chen XH, Song HX, Wang HS, Zhang G, Wang H, et al. Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res. 2014;358(2):491–502. doi:10.1007/s00441-014-1953-2.CrossRefPubMed

21.

Horng CT, Shieh PC, Tan TW, Yang WH, Tang CH. Paeonol suppresses chondrosarcoma metastasis through up-regulation of miR-141 by modulating PKCδ and c-Src signaling pathway. Int J Mol Sci. 2014;15(7):11760–72. doi:10.3390/ijms150711760.

22.

Lee H, Park M, Shin N, Kim G, Kim YG, Shin JS, et al. High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells. Biochem Biophys Res Commun. 2012;424(2):321–6. doi:10.1016/j.bbrc.2012.06.116.CrossRefPubMed

23.

Rimessi A, Zecchini E, Siviero R, Giorgi C, Leo S, Rizzuto R, et al. The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells. Cell Cycle. 2012;11(5):1040–8. doi:10.4161/cc.11.5.19520.CrossRefPubMedPubMedCentral

24.

Wu J, Zhang B, Wu M, Li H, Niu R, Ying G, et al. Screening of a PKC zeta-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis. Invest New Drugs. 2010;28(3):268–75. doi:10.1007/s10637-009-9242-8.CrossRefPubMed

25.

Giagulli C, Scarpini E, Ottoboni L, Narumiya S, Butcher EC, Constantin G, et al. RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. Immunity. 2004;20:25–35. doi:10.1016/S1074-7613(03)00350-9.CrossRefPubMed

26.

Laudanna C, Mochly-Rosen D, Liron T, Constantin G, Butcher EC. Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem. 1998;273:30306–15. doi:10.1074/jbc.273.46.30306.CrossRefPubMed

27.

Guo H, Gu F, Li W, Zhang B, Niu R, Fu L, et al. Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem. 2009;109(1):203–13. doi:10.1111/j.1471-4159.2009.05946.x.CrossRefPubMed

28.

Guo H, Ma Y, Zhang B, Sun B, Niu R, Ying G, et al. Pivotal advance: PKCzeta is required for migration of macrophages. J Leukoc Biol. 2009;85(6):911–8. doi:10.1189/jlb.0708429.CrossRefPubMed

29.

Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, et al. Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 2005;65:1433–41. doi:10.1158/0008-5472.CAN-04-1163.CrossRefPubMed

30.

Liu Y, Wang B, Wang J, Wan W, Sun R, Zhao Y, et al. Down-regulation of PKC zeta expression inhibits chemotaxis signal transduction in human lung cancer cells. Lung Cancer. 2009;63:210–8. doi:10.1016/j.lungcan.2008.05.010.CrossRefPubMed

31.

Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol. 2002;1:9–19. doi:10.1089/154065802761001266.CrossRefPubMed

32.

Barati MT, Scherzer J, Wu R, Rane MJ, Klein JB. Cytoskeletal rearrangement and Src and PI-3K-dependent Akt activation control GABA(B)R-mediated chemotaxis. Cell Signal. 2015;27(6):1178–85. doi:10.1016/j.cellsig.2015.02.022.CrossRefPubMedPubMedCentral

33.

Reinhardt B, Godfrey R, Fellbrich G, Frank H, Lüske A, Olieslagers S, et al. Human cytomegalovirus infection impairs endothelial cell chemotaxis by disturbing VEGF signalling and actin polymerization. Cardiovasc Res. 2014;104(2):315–25. doi:10.1093/cvr/cvu204.CrossRefPubMed

34.

Wang JN, Wan WZ, Sun RH, Liu Y, Sun XJ, Ma DL, et al. Reduction of Akt2 expression inhibits chemotaxis signal transduction in human breast cancer cells. Cell Signal. 2008;20(6):1025–34. doi:10.1016/j.cellsig.2007.12.023.CrossRefPubMed

35.

Wang JT, Song LZ, Li LL, Zhang W, Chai XJ, An L, et al. Src controls neuronal migration by regulating the activity of FAK and cofilin. Neuroscience. 2015;292:90–100. doi:10.1016/j.neuroscience.2015.02.025.CrossRefPubMed

36.

Wang Y, Kuramitsu Y, Kitagawa T, Baron B, Yoshino S, Maehara SI, et al. Cofilin-phosphatase slingshot-1L (SSH1L) is over-expressed in pancreatic cancer (PC) and contributes to tumor cell migration. Cancer Lett. 2015;360(2):171–6. doi:10.1016/j.canlet.2015.02.015.CrossRefPubMed

37.

Siton O, Bernheim-Groswasser A. Reconstitution of actin-based motility by vasodilator-stimulated phosphoprotein (VASP) depends on the recruitment of F-actin seeds from the solution produced by cofilin. J Biol Chem. 2014;289(45):31274–86. doi:10.1074/jbc.M114.586958.CrossRefPubMedPubMedCentral

38.

Li HY, Wu J, Ying GG, Chen LW, Lai LH, Liu Z, et al. J-4: a novel and typical preclinical anticancer drug targeting protein kinase C ζ. Anti- Cancer Drugs. 2012;23(7):691–7.CrossRefPubMed

39.

Huang X, Sun D, Pan Q, Wen WW, Chen Y, Xin XL, et al. JG6, a novel marine-derived oligosaccharide, suppresses breast cancer metastasis via binding to cofilin. Oncotarget. 2014;5(11):3568–78.CrossRefPubMedPubMedCentral

Titel: A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice
verfasst von: Jing Wu
Shuye Liu
Zhijuan Fan
Lei Zhang
Yaqiong Tian
Rui Yang
Publikationsdatum: 05.01.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 6/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4744-9

Springer Medizin

A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Immunomodulatory potencies of isolated compounds from Crataegus azarolus through their antioxidant activities

Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China

CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer

Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development

RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma

The HLA-DRB1 allele polymorphisms and nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie